Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

Ting Tsung Chang, Ching Lung Lai, Rong Nan Chien, Richard Guan, Seng Gee Lim, Chuan Mo Lee, Keng Yeen Ng, Graham J. Nicholls, Julie C. Dent, Nancy W.Y. Leung

研究成果: Article同行評審

220 引文 斯高帕斯(Scopus)

摘要

Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine treatment and the clinical relevance of the emergence of YMDD-variant hepatitis B virus (HBV). Methods: Fifty-eight Chinese adult patients with chronic hepatitis B (CHB) were randomized to lamivudine 100 mg/day for up to 5 years and were monitored for YMDD-variant HBV, hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and detectable antibody to HBeAg) and serum alanine aminotransferase (ALT) concentrations. Four-year data are reported here. Results: The rate of HBeAg seroconversion increased with extended therapy and also with higher baseline ALT concentrations. YMDD-variant HBV was detected in 67% (39/58) of patients at some point during treatment. After 4 years, a total of 47% (27/58) of patients achieved HBeAg seroconversion. Thirty-three per cent (13/39) of patients with YMDD-variant HBV achieved HBeAg seroconversion; this increased to 57% (8/14) in patients with moderately elevated (>2-5 × upper limit of normal) pre-treatment ALT concentrations. The proportion of patients that achieved normal serum ALT increased from 29% (17/58) at baseline to 69% (31/45) following 4 years of treatment. That included 68% (23/34) of patients with YMDD-variant HBV and 73% (8/11) of those without the variant. All patients receiving lamivudine had reduced serum concentrations of HBV-DNA compared with baseline, despite the emergence of YMDD-variant HBV in 39 patients. Lamivudine was generally well tolerated; there was little change in the number or type of drug-related adverse events in the fourth year of the study. Conclusions: Despite the emergence of YMDD-variant HBV, Chinese patients showed increased HBeAg seroconversion and improvement in ALT levels with an increased duration of treatment with lamivudine.

原文English
頁(從 - 到)1276-1282
頁數7
期刊Journal of Gastroenterology and Hepatology (Australia)
19
發行號11
DOIs
出版狀態Published - 2004 十一月

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

指紋 深入研究「Four years of lamivudine treatment in Chinese patients with chronic hepatitis B」主題。共同形成了獨特的指紋。

引用此